Clodronic Acid

Summary

Clodronic Acid (CHEMBL12318) is an approved small-molecule bone density conservation agent (ATC M05BA02) targeting SLC17A9; indicated across 2 conditions including bone disorder and brachial plexus neuropathy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M05BA02
• Targets: 1 (SLC17A9)
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 244.89 Da · CH4Cl2O6P2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL12318
Name	Clodronic Acid
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	25419
ChEBI	CHEBI:110423
ATC	M05BA02
Molecular formula	CH4Cl2O6P2
Molecular weight	244.89
InChIKey	ACSIXWWBWUQEHA-UHFFFAOYSA-N

SMILES: C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl

IUPAC name: [dichloro(phosphono)methyl]phosphonic acid

ChEBI definition: An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.

Pharmacological roles (ChEBI): bone density conservation agent, antineoplastic agent.

Also known as: Acide clodronique, Acido clodronico, Clodronate, Clodronic acid, bisphosphonate clodronate, clodronic acid, SID90340757, Clodronic Acid, clodronate, CLODRONIC ACID, dichloromethylenediphosphonic acid

Parent form; salt/anhydrous children: CHEMBL1520188

Patent coverage: 8,664 distinct patent families (35,336 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC17A9	Vesicular nucleotide transporter	Inhibition	7.81	0.7%	Q9BYT1

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SLC17A9.

Dominant GO biological processes

GO term	Targets
ADP transport	1
ATP transport	1
purine nucleotide import into lysosome	1
guanine nucleotide transmembrane transport	1
ATP export	1
lysosomal protein catabolic process	1
transmembrane transport	1
purine-containing compound transmembrane transport	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bone disorder	3	MONDO:0005381	EFO:0004260
brachial plexus neuropathy	3	MONDO:0006683	EFO:1000844

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	2
Not specified	2
PHASE2/PHASE3	1
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00009945	PHASE3	COMPLETED	Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer
NCT01291433	PHASE3	COMPLETED	Trial of Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy
NCT06263517	PHASE2/PHASE3	UNKNOWN	Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis Patients
NCT00658268	PHASE2	COMPLETED	Bisphosphonates and Impaction Grafting in Hip Revision
NCT03803839	EARLY_PHASE1	COMPLETED	Locally Administered Clodronate in the Prevention of Aseptic Implant Loosening
NCT07116252	Not specified	ACTIVE_NOT_RECRUITING	Effect of Different Irrigation Protocols on Postoperative Endodontic Pain and Inflammation
NCT05183308	Not specified	COMPLETED	Combined Drug Therapy in Lateral Fragility Fractures of the Femur

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).